Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial
In clinical care today, lung cancer is typically confirmed by the analysis of tissue that is directly obtained from the tumor or by analyzing cellular material e.g. from rinsing the airways with saline solution during a bronchial lavage. However, in approximately half of the suspected cancer cases neither cytology nor histology provide conclusive results at the time of a patient's first bronchoscopy. This frequently leads to further time consuming and costly procedures bearing additional risks for patients. The Epi proLung BL Reflex Assay test addresses this clear medical need by helping pathologists to confirm the presence of malignant lung disease.
"The Epi proLung BL Reflex Assay may provide critical additional information to pathologists when cytology is not unequivocal. This represents the diagnostic value of the test", stated Prof. Manfred Dietel, Director of the Institute of Pathology of Charité - University Medicine Berlin at a recent Key Opinion Leader Meeting in Frankfurt am Main, Germany, at which Epigenomics has introduced the novel test to pathologists and oncologists.
The clinical performance of the test has been demonstrated in a case control study with individuals that have undergone diagnostic work-ups for suspected lung cancer within the University of Liverpool Cancer Research Centre, Roy Castle Lung Cancer Research Program UK, under Professor John K Field. Using the Epi proLung BL Reflex Assay, the DNA methylation status of the SHOX2 gene was determined in routinely obtained bronchial lavage of patients with confirmed bronchial carcinoma and patients with no evidence of malignant lung disease but other lung diseases at the time of bronchoscopy and a minimum lung cancer free survival of 18 months. In this critical patient group, the test correctly identified 81% of the lung cancer cases with only 5% false positive results translating into a specificity of 95%. This clinical performance evaluation study confirms previous research studies showing that methylated SHOX2 DNA is a highly specific biomarker for lung cancer in bronchial lavage. Furthermore, the performance evaluation study has demonstrated that the Epi proLung BL Reflex Assay is a technically robust and reliable diagnostic tool. Simple handling, short time to results and compatibility with standard molecular diagnostic laboratory equipment are expected to facilitate introduction of this test into clinical routine.
Most read news
Topics
Organizations
Other news from the department research and development
These products might interest you
tritec® Chromatographic refrigerators by tritec für Labortechnik und Umweltsimulation
Energy-efficient chromatography refrigerators for precise temperature control
Safe storage of your HPLC systems at -5 °C to 20 °C with modern touchscreen display
Mars 6 by CEM
Everything under Control - with This Intelligent Microwave Digestion System
High Sample Throughput with Just One Click
CrystalBreeder by Technobis
CrystalBreeder: the next generation multi-reactor crystallization platform
Enhance your early stage solid state screening. New: controlled evaporation & vapor diffusion modes
Crystal16 by Technobis
Crystal16 - the ultimate instrument for research and process development
Upgrade your crystallization screens with the next generation benchtop crystallization system
OHAUS Laboratory equipment by Ohaus
Do More with OHAUS Laboratory Equipment
Do Not Limit Yourself to Just Measurement! Discover Ingenious Portfolio
FlowSyn and FlowSyn Maxi by Uniqsis
Continuous Flow Chemistry Systems for reaction optimisation and scale up
Perform reactions up to 300°C and 100 bar from 0.1 - 100 ml /minute
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.